Get the weekly note
ETFIQetfiq.com · independent ETF data

Data as of .

FBT vs GNMX: which is really different?

FBT and GNMX hold 24% of their weight in the same names.

First Trust NYSE Arca Biotechnology Index Fund and Corgi Genomics & Precision Medicine ETF.

23.6%FBT in the S&P 500
26.7%GNMX in the S&P 500
+48.9%FBT total return, 1 year
+41.2%GNMX total return, 1 year

ETFIQ Off-Index Score: GNMX scores higher

How much of it is not the index it is sold as an alternative to?

FBT 64.1GNMX 67.40.1, the lowest in this set91.8, the highest

A percentile among the 379 thematic ETFs with a holdings filing. It is a position in a set, not a rating, and neither end of it is a recommendation. All thematic ETFs ranked by it · How it is computed

FBT76% of its weight is outside the S&P 500 · 1 year to Sep 18, 2026
24%76%in the S&P 500of its weight outside the S&P 500active share 99% · top ten 39% of the fund · 31 holdings filed Sep 18, 2026 · Nasdaq-100: 16% in24%76%inoutside the S&P 500active share 99% · top ten 39% of the fund
GNMX73% of its weight is outside the S&P 500 · 3 months to Sep 18, 2026
27%73%in the S&P 500of its weight outside the S&P 500active share 99% · top ten 45% of the fund · 58 holdings filed Sep 18, 2026 · Nasdaq-100: 9% in27%73%inoutside the S&P 500active share 99% · top ten 45% of the fund

24% of the two portfolios are the same securities at the same weight.

What they hold in common

By the books each fund has filed, FBT and GNMX hold 24% of their money in the same securities at the same weight.

Positions FBT and GNMX both hold, largest shared weight first
HoldingFBTGNMX
Illumina, Inc.3.90%4.36%
Vertex Pharmaceuticals Incorporated3.24%5.89%
Genmab A/S (ADR)3.71%2.91%
Incyte Corporation3.33%2.90%
Alnylam Pharmaceuticals, Inc.2.48%2.64%
BioMarin Pharmaceutical Inc.3.35%2.22%
Bio-Techne Corporation3.14%2.20%
NeoGenomics, Inc.4.37%1.60%
Veracyte, Inc.2.16%1.16%
Sarepta Therapeutics, Inc.3.29%0.93%
Only in each
Only in FBTOnly in GNMX
Halozyme Therapeutics, Inc. 4.57%Thermo Fisher Scientific Inc 8.62%
Natera, Inc. 4.24%Moderna Inc 7.05%
Repligen Corporation 3.80%Guardant Health Inc 3.86%
Corcept Therapeutics Inc. 3.72%10X Genomics Inc 3.42%
Regeneron Pharmaceuticals, Inc. 3.66%Revolution Medicines Inc 3.27%
BeOne Medicines Ltd. (ADR) 3.64%Twist Bioscience Corp 2.86%
Gilead Sciences, Inc. 3.58%First American Government Obligations Fu 2.62%
argenx SE (ADR) 3.50%Iovance Biotherapeutics Inc 2.30%

Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Sep 18, 2026.

Performance, window by window

FBT and GNMX over each window. Every figure is an ETFIQ calculation with distributions reinvested. Source: ETFIQ.
WindowTotal returnvs the S&P 500vs the Nasdaq-100
FBTGNMXFBTGNMXFBTGNMX
3 months+17.2%+29.7%+14.9 pts+27.4 pts+19.6 pts+32.2 pts
6 months+40.6%not published+22.6 ptsnot published+16.4 ptsnot published
1 year+48.9%not published+32.3 ptsnot published+27.1 ptsnot published
3 years+80.7%not published+2.3 ptsnot published−17.5 ptsnot published
Since launch+848.2%+41.2%+44.6 pts+36.9 pts−842.1 pts+37.4 pts
Open the live comparison on ETFIQ
FBT and GNMX on the same fields, as of Sep 18, 2026. Source: ETFIQ.
FBT
First Trust NYSE Arca Biotechnology Index Fund
Holds 31 stocks in biotech, 24% of its weight in S&P 500 companies
GNMX
Corgi Genomics & Precision Medicine ETF
Holds 58 stocks in genomics and gene editing, 27% of its weight in S&P 500 companies
IssuerFirst TrustCorgi
ThemeBiotechGenomics and gene editing
In the S&P 50023.6%26.7%
Active share vs the S&P 50099.1%99.4%
In the Nasdaq-10016.2%8.5%
Holdings3158
Top ten, share of the fund39.2%45.1%
Expense ratio0.55%0.35%
Fee for the differing part0.55%0.35%
Total return, 1 year+48.9%+41.2% (since launch on May 6, 2026)
vs the S&P 500+32.3 pts+36.9 pts
vs the Nasdaq-100+27.1 pts+37.4 pts
Below its high−2.1%−1.0%
Net assets$2.9bn$3m

FBT in plain words

By weight, 24% of FBT's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 99%. The top ten holdings are 39% of the fund across 31 positions, as published by its issuer for Sep 18, 2026. Over the year to Sep 18, 2026 the fund returned +48.9% with distributions reinvested against +16.6% for the S&P 500, so a holder was ahead by 32.3 pts.

GNMX in plain words

By weight, 27% of GNMX's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 99%. The top ten holdings are 45% of the fund across 58 positions, as published by its issuer for Sep 18, 2026. Since it launched on May 6, 2026 the fund returned +41.2% with distributions reinvested against +4.3% for the S&P 500, so a holder was ahead by 36.9 pts.

Questions people ask

Do FBT and GNMX hold the same stocks?
By their latest filings, 24% of their books are the same securities at the same weight, which is a meaningful overlap. Overlap is the sum of the smaller weight of every security they share.
Which is more different from the S&P 500, FBT or GNMX?
FBT has 24% of its weight in S&P 500 names and GNMX has 27%, so GNMX differs more from the index.
Which is cheaper, FBT or GNMX?
FBT charges 0.55% a year and GNMX charges 0.35%, so GNMX is cheaper. Fees come from each fund's prospectus.

Other comparisons

Where these figures came from

ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.

FBT against GNMX, ETFIQ, data as of Sep 18, 2026. Every figure is calculated from a named public source; the method is at etfiq.com/methodology. A comparison is not a recommendation.

Cite this page. ETFIQ, FBT against GNMX, data as of Sep 18, 2026. https://etfiq.com/compare/themes/fbt-vs-gnmx Free to use with attribution; the underlying files are at Open data.

How every figure is computed · Standards and sources